George King, MD
Endocrinology, Diabetes & Metabolism · Boston, MANPI 1669458816
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,095 of the $23,877 with a category attached, or 67.4%. 4 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 53.4% of the total. Reporting peaked in 2019 at $12,852 and has fallen 68.5% since, to $4,050 in 2022.
Across 14 payments — averaging $1705.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$13K
- Medtronic$10K
- Agios Pharmaceuticals, Inc.$1K
- Novo Nordisk US Research & Development, Inc.$100
Across 11 payments — averaging $336,573 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson$2.1M
- Janssen Research & Development, LLC$878K
- Sanofi US Services Inc.$697K
What the payments were for
- Consulting fees$16,09567%
- Speaking & faculty fees$5,85025%
- Travel & lodging$1,5547%
- Food & beverage$3782%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 7 | $12,752 |
| Medtronic(2 entities) | 5 | $9,900 |
| Agios Pharmaceuticals, Inc. | 1 | $1,125 |
| Novo Nordisk US Research & Development, Inc. | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$12,688
- SAR439977$12,688
How this compares
$23,877 in reported general payments places this provider in the 85th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 134 | $183,955 |
| JanuviaSitagliptin Phosphate | 64 | $93,371 |
| TrulicityDulaglutide | 26 | $46,255 |
| FarxigaDapagliflozin Propanediol | 20 | $31,777 |
| TradjentaLinagliptin | 22 | $30,375 |
| OzempicSemaglutide | 11 | $10,266 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $6,834 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 34 | $4,778 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 18 | $3,519 |
| Acarbose | 54 | $3,258 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $3,130 |
| LantusInsulin Glargine,hum.Rec.Anlog | 11 | $2,880 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 13 | $1,858 |
| Insulin SyringeSyringe-Needle,insulin,0.5 Ml | 13 | $1,130 |
| Metformin Hcl | 107 | $816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCLantus | $12,752 | $2,88011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Boston
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Augusto Caballero-RoblesBoston$150K
- Osama HamdyBoston$117K
- Barbara KahnBoston$105K
- Naomi FisherBoston$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.